EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors

Neil D Almeida, Sarthak Sinha, Mengyu Fang, Harshini Cheruvu, Roshan Tasgaonkar, Babar Gulzar, Venkatesh Madhugiri, Victor Goulenko, Dheerendra Prasad

Journal of Neuro-Oncology · 2026-07 · 178 (3)

DOI: 10.1007/s11060-026-05692-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 03.07.2026. Verfasst von Neil D Almeida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm St, Buffalo, NY, 14203, USA. Hauptthemen laut MEDLINE: Radiosurgery, Brain Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roswell Park Cancer Institute and National Cancer Institute (NCI) grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brain metastases from renal cell carcinoma (RCC) are uncommon but clinically consequential. We evaluated survival, intracranial failure, lesion-level local failure, and MRI volumetric response after Gamma Knife radiosurgery (GKRS), including associations with systemic therapy exposure.

Methods

We retrospectively identified patients treated with GKRS for intracranial RCC metastases (2001–2025). Systemic therapy exposure (TKI and/or immunotherapy) was captured time-agnostically. Overall survival (OS) and patient-level intracranial treatment failure were analyzed using Kaplan–Meier/Cox models. Lesion-level treatment failure was analyzed using clustered generalized estimating equations (GEE). Six-month volumetric response was assessed using an epsilon-stabilized log volume ratio ln{(V 6m +ϵ)/(V GKRS +ϵ)}, ε = 0.01.

Results

Thirty-four patients (87 lesions) were treated; 22 deaths occurred. Overall survival was numerically longer among patients who received systemic therapy compared with those who did not, although this did not reach statistical significance (log-rank p = 0.058). In a parsimonious adjusted Cox model, TKI exposure was associated with improved OS (aHR 0.191; 95% CI 0.062–0.593; p = 0.004), as was higher KPS (HR 0.37 per 10-point increase; 95% CI 0.21–0.63; p < 0.001). Ten patient-level intracranial treatment failure events occurred, without significant differences by systemic therapy exposure. At the lesion level, 15/87 lesions failed; postoperative cavities had higher failure than intact lesions (71.4% vs. 12.5%; p = 0.001) and remained associated with failure after clustered adjustment (OR 9.92; 95% CI 1.44–68.27; p = 0.020). Dmax was not correlated with 6-month log volume ratio (ρ=−0.075; p = 0.535), but poorer 6-month volumetric response was associated with subsequent lesion failure ( p = 0.0023; clustered OR 2.84; 95% CI 1.16–6.96; p = 0.023).

Conclusions

In RCC brain metastases treated with GKRS, postoperative cavities showed a higher observed rate of local failure than intact lesions, although this finding should be interpreted cautiously given the small number of cavity targets. While Dmax was not associated with early volumetric change, early 6-month volumetric trajectory was associated with subsequent local failure, suggesting a pragmatic imaging marker for risk-adapted surveillance and salvage planning. Systemic therapy exposure, particularly TKIs, was associated with OS in adjusted analysis, whereas intracranial treatment failure did not differ by systemic exposure in this cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryBrain NeoplasmsCarcinoma, Renal CellKidney NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedPrognosisTreatment FailureFollow-Up StudiesSurvival RateAdultAged, 80 and over

Stichwörter der Autor:innen

Brain metastasesGamma knife radiosurgeryImmunotherapyLocal controlPostoperative cavityRenal cell carcinomaTyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm St, Buffalo, NY, 14203, USA.
  • Department of Radiation Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Statistics & Data Science, Cornell University, Ithaca, NY, USA.
  • Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm St, Buffalo, NY, 14203, USA. d.prasad@roswellpark.org.
  • Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. d.prasad@roswellpark.org.

Förderung

  • Roswell Park Cancer Institute and National Cancer Institute (NCI) grants

Zitieren

APA

Almeida, N. D., Sinha, S., Fang, M., Cheruvu, H., Tasgaonkar, R., Gulzar, B., Madhugiri, V., Goulenko, V., & Prasad, D. (2026). Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors. Journal of Neuro-Oncology, 178(3). https://doi.org/10.1007/s11060-026-05692-3

Vancouver

Almeida ND, Sinha S, Fang M, Cheruvu H, Tasgaonkar R, Gulzar B, et al. Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors. Journal of Neuro-Oncology. 2026;178(3). doi:10.1007/s11060-026-05692-3

BibTeX
@article{Almeida2026,
  author = {Almeida, Neil D and Sinha, Sarthak and Fang, Mengyu and Cheruvu, Harshini and Tasgaonkar, Roshan and Gulzar, Babar and Madhugiri, Venkatesh and Goulenko, Victor and Prasad, Dheerendra},
  title = {Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  volume = {178},
  number = {3},
  doi = {10.1007/s11060-026-05692-3}
}
Kostenlos starten →